Big changes are happening at Auris Medical Holding Ltd. (NASDAQ:EARS), which makes the stock worth watching today. The company is among the top gainers of the stock market today, skyrocketing 4.89% or (0.13 points) to $2.89 from its previous close of $2.76. Does this growth mean it the best stock to buy right now? The shares seem to have an active trading volume day with a reported 200600 contracts so far this session. EARS shares had a relatively better volume day versus average trading capacity of 231.86 thousand shares, but with a 1.59 million float and a 8.66% run over a week, it’s definitely worth keeping an eye on. The one year price forecast for EARS stock indicates that the average analyst price target is $50.08 per share. This means the stock has a potential increase of 1632.87% from where the EARS share price has been trading recently which is between $2.7087 and $3.0739. There are some brokerage firms that offer lower targets than the average, with one of them, even setting their price target at $50.
The shorts are climbing into Auris Medical Holding Ltd. (EARS) stock. The latest set of short interest data was released on 31 May 2019, and the numbers show a rise in short interest in EARS shares. While short interest still represents only 4.59% of EARS’s float, the number of shares shorted have risen by 54554. The number of shares shorted advanced to 127777 shares, up from 73223 shares during the preceding fortnight. With average daily trading volumes at 299325 shares, days to cover decreased to about 1 days. The most recent news story about the stock that appeared in Yahoo Finance‘s news section was titled “Auris Medical Holding Ltd Provides Corporate Update” and dated May 23, 2019.
During the recent trading session for Auris Medical Holding Ltd. (NASDAQ:EARS), the company witnessed their stock drop by $-0.09 over a week and tumble down $-0.87 from the price 20 days ago. When compared to their established 52-week high of $39.4, the high they recorded in their recent session happens to be lower. Their established 52-week high was attained by the company on 10/15/18. The recent low of $2.41 stood for a -92.65% since 04/06/19, a data which is good for most investors who are looking to take advantage of the stock’s recent rise. A beta of -0.06 is also allocated to the stock. Since the beta is less than one, it implies that the stock is more volatile than the market, a data that traders are keeping close attention to.
Looking at the current readings for Auris Medical Holding Ltd., the two-week RSI stands at 36.52. This figure suggests that EARS stock, for now, is neutral, meaning that the shares are stable in terms of price movement. The stochastic readings, on the other hand, based on the current EARS readings is similarly very revealing as it has a stochastic reading of 50.95% at this stage. This figure means that EARS share price today is being neutral.
Technical chart claims that Auris Medical Holding Ltd. (EARS) would settle between $2.99/share to $3.21/share level. However, if the stock price goes below the $2.62 mark, then the market for Auris Medical Holding Ltd. becomes much weaker. If that happens, the stock price might even plunge as low as $2.48 for its downside target. The stock is currently in the green zone of MACD, with the indicator reading 0.04. Traders are always alerted for the move of a stock above or below the zero line due to the fact that the reading is an indicator of the position of the short-term average relative to the long-term average. If the MACD is above the zero line, then the short-term average relative is above that of the long-term average, thus implying an upward momentum. Vice versa is the case if the MACD is below the zero line.
Analysts at Euro Pacific Capital, assumed coverage of EARS assigning Buy rating, according to their opinion released on October 08. ROTH Capital, analysts launched coverage of Auris Medical Holding Ltd. (NASDAQ:EARS) stock with a Buy recommendation, according to their flash note issued to investors on April 13. Analysts at Needham are sticking to their Buy stance. However, on August 19, they lifted price target for these shares to $5 from $11.
EARS equity has an average rating of 2, with the figure leaning towards a bullish end. 1 analysts who tracked the company were contacted by Reuters. Amongst them, 0 rated the stock as a hold while the remaining 1 were split even though not equally. Some analysts rate the stock as a buy or a strong buy while no rated it as a sell. 1 analysts rated Auris Medical Holding Ltd. (NASDAQ:EARS) as a buy or a strong buy while not a single analyst advised that investors should desist from purchasing the stock or sell them if they already own the company’s stock.